<DOC>
	<DOCNO>NCT01468714</DOCNO>
	<brief_summary>This study evaluate potential drug-drug interaction PF-04937319 ketoconazole , potent inhibitor drug metabolize enzyme CYP3A .</brief_summary>
	<brief_title>A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Body Mass Index ( BMI ) 17.5 29.9 kg/m2 ; total body weight &gt; =50 kg ( 110 lb ) . Subjects childbearing potential must agree use highly effective method contraception throughout study least 28days last dose treatment . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception Consumption grapefruitcontaining product within 7 day prior first dose study medication study protocol least 14 day prior first dose study medication least 28 day last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Drug Interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>ketoconazole</keyword>
	<keyword>CYP3A</keyword>
</DOC>